Vertebral refracture following percutaneous vertebral augmentation (PVA) is commonly seen in elderly patients with osteoporotic thoracolumbar compression fractures (OTLCF). It can lead to recurrent pain, loss of vertebral height, progression of kyphosis, and even neurological dysfunction, significantly impairing patients′ quality of life. Current diagnosis and treatment face multiple challenges, including high misdiagnosis rate, difficulty in choosing between surgical and non-surgical treatment options, lack of standardized surgical protocols, interference from intralesional bone cement during procedures, inadequate stability of internal fixation in osteoporotic bone, and suboptimal compliance of anti-osteoporotic therapy. Establishing a standardized diagnostic and therapeutic framework is urgently needed. To standardize the management process and improve outcomes for vertebral refractures after PVA in elderly OTLCF patients, Spinal Trauma Group of the Orthopedic Branch of Chinese Medical Doctor Association organized experts in the field to develop Guideline for the diagnosis and treatment of vertebral refracture after percutaneous vertebral augmentation in elderly patients with osteoporotic thoracolumbar compression fractures ( version 2025), based on current literature and clinical experience, and adhering to principles of scientific rigor and clinical applicability. A total of 11 recommendations were proposed, encompassing diagnosis, treatment, and rehabilitation of vertebral refracture after PVA in elderly patients with OTLCF, aiming to provide a foundation for a standardized management.

Objective To investigate the efficacy of ganciclovir combined with spleen aminopeptide in treating infectious mononucleosis(IM)and its impact on the immune function of diseased children.Methods Totally 120 diseased children with IM accepted by our hospital from February 2022 to August 2024 were stochastically assigned into a treatment group and a monotherapy group.The monotherapy group received treatment with ganciclovir,while the treatment group received treatment with spleen aminopeptide in addition to the monotherapy group.The efficacy,symptom improvement time,serum inflammatory factors,immune indicators,and biochemical indicators before and after treatment were compared between the two groups.Results The efficacy of the treatment group was better than that of the monotherapy group,and the symptom relief time was shorter than that of the monotherapy group(P＜0.05).After treatment,the serum amyloid A,TNF-α,IL-6,procalcitonin,CD3+T,CD8+T,lactate dehydrogenase,alanine aminotransferase,EBV-DNA,creatine kinase,and white blood cell count in both groups decreased,while CD4+T and CD4+T/CD8+T increased.The amplitude of the treatment group was greater than that of the monotherapy group(P＜0.05).Conclusion The combination of ganciclovir and spleen aminopeptide in treating IM is beneficial for enhancing the immune function of T lymphocytes of diseased children,alleviating inflammatory reactions,improving biochemical indicators,and enhancing efficacy.

Objective To investigate the efficacy of ganciclovir combined with spleen aminopeptide in treating infectious mononucleosis(IM)and its impact on the immune function of diseased children.Methods Totally 120 diseased children with IM accepted by our hospital from February 2022 to August 2024 were stochastically assigned into a treatment group and a monotherapy group.The monotherapy group received treatment with ganciclovir,while the treatment group received treatment with spleen aminopeptide in addition to the monotherapy group.The efficacy,symptom improvement time,serum inflammatory factors,immune indicators,and biochemical indicators before and after treatment were compared between the two groups.Results The efficacy of the treatment group was better than that of the monotherapy group,and the symptom relief time was shorter than that of the monotherapy group(P＜0.05).After treatment,the serum amyloid A,TNF-α,IL-6,procalcitonin,CD3+T,CD8+T,lactate dehydrogenase,alanine aminotransferase,EBV-DNA,creatine kinase,and white blood cell count in both groups decreased,while CD4+T and CD4+T/CD8+T increased.The amplitude of the treatment group was greater than that of the monotherapy group(P＜0.05).Conclusion The combination of ganciclovir and spleen aminopeptide in treating IM is beneficial for enhancing the immune function of T lymphocytes of diseased children,alleviating inflammatory reactions,improving biochemical indicators,and enhancing efficacy.

Vertebral refracture following percutaneous vertebral augmentation (PVA) is commonly seen in elderly patients with osteoporotic thoracolumbar compression fractures (OTLCF). It can lead to recurrent pain, loss of vertebral height, progression of kyphosis, and even neurological dysfunction, significantly impairing patients′ quality of life. Current diagnosis and treatment face multiple challenges, including high misdiagnosis rate, difficulty in choosing between surgical and non-surgical treatment options, lack of standardized surgical protocols, interference from intralesional bone cement during procedures, inadequate stability of internal fixation in osteoporotic bone, and suboptimal compliance of anti-osteoporotic therapy. Establishing a standardized diagnostic and therapeutic framework is urgently needed. To standardize the management process and improve outcomes for vertebral refractures after PVA in elderly OTLCF patients, Spinal Trauma Group of the Orthopedic Branch of Chinese Medical Doctor Association organized experts in the field to develop Guideline for the diagnosis and treatment of vertebral refracture after percutaneous vertebral augmentation in elderly patients with osteoporotic thoracolumbar compression fractures ( version 2025), based on current literature and clinical experience, and adhering to principles of scientific rigor and clinical applicability. A total of 11 recommendations were proposed, encompassing diagnosis, treatment, and rehabilitation of vertebral refracture after PVA in elderly patients with OTLCF, aiming to provide a foundation for a standardized management.

Objective:To evaluate the analgesic efficacy of supra-inguinal fascia iliac compartment block (S-FICB)in patients with hip fracture.Methods:This study was a single-center, randomized controlled trial. Forty-eight patients who were admitted to the emergency department due to clinically diagnosed femoral neck or intertrochanteric fractures from April to September 2023 were selected. A random sequence was generated using IBM SPSS Statistics 20, and the patients were divided into 2 groups in a 1∶1 ratio( n=24 each): S-FICB group and infra-inguinal fascia iliac compartment block (I-FICB) group. Both groups received nerve blocks under ultrasound guidance, with an injection of 0.25% ropivacaine 40 ml. The primary outcome measure was sufentanil consumption within 24 h post-block. Secondary outcome measures included the distribution of local anesthetic spread as observed on CT at 0.5 h post-block, the extent of hip skin sensory reduction to pinprick, the time to first analgesic pump pressing, the number of effective analgesic pump pressing within 24 h post-block, the Numeric Rating Scale (NRS) score for pain during passive movement at 0.5 h post-block, and the static NRS scores at baseline (pre-block) and at 0.5, 3, 6, 12 and 24 h post-block. Results:Compared to I-FICB group, the consumption of sufentanil was significantly decreased, the coverage of lumbar plexus nerve branches by local anesthetics was increased, NRS scores were decreased during passive movement, the time to the first analgesic pump pressing was prolonged, the number of effective pump pressing was reduced, and static NRS scores were decreased at 24 h post-block in S-FICB group( P<0.01). In I-FICB group, no local anesthetic coverage of the iliohypogastric or ilioinguinal nerves was observed. Neither group showed coverage of the obturator nerve by the local anesthetic. Conclusions:Compared to I-FICB, S-FICB (0.25% ropivacaine 40 ml) provides a wider range of local anesthetic spread and can cover more branches of the lumbar plexus, which exerts better analgesic efficacy in patients with hip fracture. However, neither approach directly blocks the obturator nerve.

Objective:To evaluate the analgesic efficacy of supra-inguinal fascia iliac compartment block (S-FICB)in patients with hip fracture.Methods:This study was a single-center, randomized controlled trial. Forty-eight patients who were admitted to the emergency department due to clinically diagnosed femoral neck or intertrochanteric fractures from April to September 2023 were selected. A random sequence was generated using IBM SPSS Statistics 20, and the patients were divided into 2 groups in a 1∶1 ratio( n=24 each): S-FICB group and infra-inguinal fascia iliac compartment block (I-FICB) group. Both groups received nerve blocks under ultrasound guidance, with an injection of 0.25% ropivacaine 40 ml. The primary outcome measure was sufentanil consumption within 24 h post-block. Secondary outcome measures included the distribution of local anesthetic spread as observed on CT at 0.5 h post-block, the extent of hip skin sensory reduction to pinprick, the time to first analgesic pump pressing, the number of effective analgesic pump pressing within 24 h post-block, the Numeric Rating Scale (NRS) score for pain during passive movement at 0.5 h post-block, and the static NRS scores at baseline (pre-block) and at 0.5, 3, 6, 12 and 24 h post-block. Results:Compared to I-FICB group, the consumption of sufentanil was significantly decreased, the coverage of lumbar plexus nerve branches by local anesthetics was increased, NRS scores were decreased during passive movement, the time to the first analgesic pump pressing was prolonged, the number of effective pump pressing was reduced, and static NRS scores were decreased at 24 h post-block in S-FICB group( P<0.01). In I-FICB group, no local anesthetic coverage of the iliohypogastric or ilioinguinal nerves was observed. Neither group showed coverage of the obturator nerve by the local anesthetic. Conclusions:Compared to I-FICB, S-FICB (0.25% ropivacaine 40 ml) provides a wider range of local anesthetic spread and can cover more branches of the lumbar plexus, which exerts better analgesic efficacy in patients with hip fracture. However, neither approach directly blocks the obturator nerve.

Objective To examine the short-and middle-term efficacy and refracture rate in patients with thoracolumbar fracture having percutaneous kyphoplasty (PKP) and determine their correlation with the severity of osteoporosis.Methods A retrospective analysis was conducted on 247 patients with thoracolumbar fracture undergone PKP from January 2008 to February 2014.Mean age of the patients (94 males and 153 females) was 63.2 years (range,50-81 years).Ground-level falls occurred in 119 patients,traffic injuries in 72 patients and high falls in 56 patients.The patients were assigned to osteopenia group and osteoporosis group based on the preoperative bone mineral density.Visual analogue score (VAS),Roland-Morris disability survey scale (RDQ),vertebral compression rate,kyphotic Cobb angle and refracture rate were recorded before and after operation.Efficacy in correlation with the severity of osteoporosis was evaluated.Results Mean duration of follow-up was 24.3 months (range,18-36 months).Three days after operation,VAS descended from (7.7 ± 2.1) points to (4.3 ± 1.1) points in osteopenia group and from (7.7 ± 2.0) points to (4.2 ± 1.5) points in osteoporosis group (P ＜ 0.05);RDQ descended from (21.2 ± 1.5) points to (10.4 ± 2.5) points in osteopenia group and from (20.8 ± 1.9) points to (11.2 ± 1.7) points in osteoporosis group (P ＜ 0.05);rate of vertebral body compression descended from (42.2 ± 10.5) ％ to (3.2 ± 0.5) ％ in osteopenia group and from (46.2 ± 12.7) ％ to (2.9 ± 0.8) ％ in osteoporosis group (P ＜ 0.05);kyphotic Cobb angle descended from (21.2 ± 9.5) ° to (7.2 ±2.4) °in osteopenia group and from (23.1 ± 8.9) ° to (7.1 ± 2.6) ° in osteoporosis group (P ＜ 0.05).Three years after operation,all the parameters remained better than these before operation,with the value higher in osteoporosis group than in osteopenia group (P ＜ 0.05).Rate of refracture was higher in osteoporosis group after operation,compared to that in osteopenia group (P ＜ 0.05).Conclusions The clinical short-term result is satisfactory,but refracture rate is increased with the osteoporosis aggravation.Targeting osteoporosis therapy is important to obtain a better mid-term results.

Objective:To detect the expression of microRNA-218 (miR-218) in human acute lymphocyte leukemia (ALL) T lymphocytes ( CCRF-CEM) ,explore its effects on the biological features of CCRF-CEM cells and the expression of its target gene c-kit, so as to provide new insights for leukemia treatment.Methods: Using the quantitative real-time polymerase chain reaction ( qRT-PCR) ,we detected the expression of miR-218 in the normal peripheral blood T lymphocytes and CCRF-CEM cells.Forty-eight hours after the miR-218 mimic was transfected into the CCRF-CEM cells,the expression of miR-218 in the CCRF-CEM cells was detected by qRT-PCR.The effect of miR-218 on the CCRF-CEM cell viability was detected using MTT.The effect of miR-218 on the proliferation and apoptosis of CCRF-CEM cell was analyzed using flow cytometry.c-kit gene was identified to be a target gene of miR-218 by luciferase reporter enzyme system,and the effect of miR-218 on the expression of KIT protein in cells were determined using Western blot.Results:As shown by qRT-PCR,compared with that in the normal peripheral blood T lymphocytes,the expressions of miR-218 in ALL T lymphocytes cell lines were significantly decreased ( P<0.01 ) .Compared with the control group, the expression of miR-218 increase significantly in CCRF-CEM cells transfected with miR-218 mimic for 48 hours ( P<0.01).MTT showed that the cell viability decreased significantly after the over-expression of miR-218 in the CCRF-CEM cells ( P<0.05 ) .Flow cytometry showed that the S-phase fraction significantly declined after the over-expression of miR-218 ( P<0.01 ) , and meanwhile the apoptosis of cells also significantly increased (P<0.01).Luciferase reporter gene assay showed that,compared with the control group,the relative luciferase activity significantly declined in the miR-218 mimic transfection group (P<0.01).Compared with the control group,the expression of KIT protein in the CCRF-CEM cells transfected with miR-218 mimic for 48 hours significantly decreased ( P<0.01).Conclusion:The expression of miR-218 decreases in ALL T lymphocytes cell lines.MiR-218 can negatively regulate the expression of KIT protein,inhibit the proliferation and increase the apoptosis of CCRF-CEM cells.Treatment based on the enhanced expression of miR-218 may be a promising strategy for leukemia.

Adolescent ; Adult ; Child ; Cord Blood Stem Cell Transplantation ; Female ; Hematopoietic Stem Cell Transplantation ; methods ; Humans ; Leukemia, Myeloid, Accelerated Phase ; therapy ; Male ; Middle Aged ; Siblings ; Tissue Donors ; Transplantation, Homologous ; Young Adult